TITLE:
Preliminary Clinical Observation on Platelet Activation Markers and CD8+PD-1+ Expression in Relation to Breast Cancer Metastasis Risk
AUTHORS:
Qihuang Chen, Xiaofang Long, Meilin Chen, Shuanquan Lin, Dan Liang, Guangliu Zeng, Shanlin Huang, Chaojun Zhang
KEYWORDS:
Breast Cancer, Metastasis, Platelet Activation, PD-1, Predictive Value
JOURNAL NAME:
Journal of Biosciences and Medicines,
Vol.14 No.6,
June
23,
2026
ABSTRACT: Objective: To preliminarily investigate the changes in platelet activation markers and CD8+ T cell PD-1 expression levels in the peripheral blood of breast cancer patients and their relationship with metastasis. Methods: A total of 32 breast cancer patients who consecutively visited Qinzhou First People’s Hospital from February 2023 to January 2025 and met the inclusion/exclusion criteria were enrolled. According to TNM staging, they were divided into early-stage breast cancer (Stage I-II, n = 16) and locally advanced/metastatic breast cancer (Stage III-IV, n = 16). Additionally, 20 healthy individuals undergoing routine physical examinations during the same period were recruited as the healthy control group. All blood samples were collected before the first biopsy or surgery and prior to any anti-tumor treatment (including neoadjuvant chemotherapy, radiotherapy, or targeted therapy). Flow cytometry was used to detect platelet membrane glycoproteins (CD41+/PLT, CD42a+, CD42b+/PLT, CD61+/PLT), platelet activation markers (CD41+CD62P+%, CD61+CD62P+%, CD41+CD61+CD62P+%), and CD8+PD-1+% expression levels. The associations between these indicators and breast cancer metastasis were analyzed. Results: There were no significant differences in platelet membrane glycoprotein expression among the three groups (P > 0.05). The platelet activation markers and CD8+PD-1+% in the locally advanced/metastatic group were significantly higher than those in the early-stage group and the healthy control group (P Conclusion: Combined detection of platelet activation markers and CD8+PD-1+% may serve as potential reference indicators for monitoring disease progression in breast cancer patients.